Using the molecular classification of glioblastoma to inform personalized treatment

Glioblastoma is the most common and most aggressive diffuse glioma, associated with short survival and uniformly fatal outcome, irrespective of treatment. It is characterized by morphological, genetic and gene‐expression heterogeneity. The current standard of treatment is maximal surgical resection, followed by radiation, with concurrent and adjuvant chemotherapy. Due to the heterogeneity, most tumours develop resistance to treatment and shortly recur. Following recurrence, glioblastoma is quickly fatal in the majority of cases. Recent genetic molecular advances have contributed to a better understanding of glioblastoma pathophysiology and disease stratification. In this paper we review basic glioblastoma pathophysiology, with emphasis on clinically relevant genetic molecular alterations and potential targets for further drug development. Copyright © 2013 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

[1]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[2]  Se Hoon Kim,et al.  Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. , 2013, Cancer cell.

[3]  Candace Chisolm,et al.  Glioblastoma with Oligodendroglioma Component (GBM‐O): Molecular Genetic and Clinical Characteristics , 2013, Brain pathology.

[4]  J. D. de Groot,et al.  Acquired Resistance to Anti-VEGF Therapy in Glioblastoma Is Associated with a Mesenchymal Transition , 2013, Clinical Cancer Research.

[5]  Wielisław Papierz,et al.  Screening for EGFR Amplifications with a Novel Method and Their Significance for the Outcome of Glioblastoma Patients , 2013, PloS one.

[6]  Juan F. García,et al.  Codeletion of 1p and 19q determines distinct gene methylation and expression profiles in IDH-mutated oligodendroglial tumors , 2013, Acta Neuropathologica.

[7]  Fang Wang,et al.  An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells , 2013, Science.

[8]  Y. Suh,et al.  Glioblastoma with oligodendroglial component represents a subgroup of glioblastoma with high prevalence of IDH1 mutation and association with younger age , 2013, Journal of Neuro-Oncology.

[9]  K. McDonald,et al.  Interleukins in glioblastoma pathophysiology: implications for therapy , 2013, British journal of pharmacology.

[10]  Juan A. Martell,et al.  Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial , 2013, BMC Cancer.

[11]  G. Reifenberger,et al.  Predictive impact of MGMT promoter methylation in glioblastoma of the elderly , 2012, International journal of cancer.

[12]  D. Brat,et al.  Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma , 2012, Science.

[13]  S. Vandenberg,et al.  EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway , 2012, Oncogene.

[14]  M. Nikiforova,et al.  Paradoxical Relationship Between the Degree of EGFR Amplification and Outcome in Glioblastomas , 2012, The American journal of surgical pathology.

[15]  K. Aldape,et al.  Low rate of R132H IDH1 mutation in infratentorial and spinal cord grade II and III diffuse gliomas , 2012, Acta Neuropathologica.

[16]  R. McLendon,et al.  Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas , 2012, Oncotarget.

[17]  K. Aldape,et al.  Absence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adults. , 2012, Annals of diagnostic pathology.

[18]  Tahsin Kurc,et al.  The tumor microenvironment strongly impacts master transcriptional regulators and gene expression class of glioblastoma. , 2012, The American journal of pathology.

[19]  Nicole S. Bryce,et al.  p38 MAPK inhibitors attenuate pro-inflammatory cytokine production and the invasiveness of human U251 glioblastoma cells , 2012, Journal of Neuro-Oncology.

[20]  T. Jiang,et al.  Glioblastoma with an oligodendroglioma component: distinct clinical behavior, genetic alterations, and outcome. , 2012, Neuro-oncology.

[21]  K. Ichimura.  Molecular pathogenesis of IDH mutations in gliomas , 2012, Brain Tumor Pathology.

[22]  Wei Wu,et al.  Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers , 2012, The Journal of pathology.

[23]  J. Uhm.  IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype , 2012 .

[24]  Tzong-Shiue Yu,et al.  A restricted cell population propagates glioblastoma growth after chemotherapy , 2012 .

[25]  R. Verhaak,et al.  Studying a complex tumor: potential and pitfalls. , 2012, Cancer journal.

[26]  C. Kruchko,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. , 2012, Neuro-oncology.

[27]  P. Cassoni,et al.  MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors , 2012, Journal of Neuro-Oncology.

[28]  R. Mirimanoff,et al.  Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial , 2012, Acta Neuropathologica.

[29]  S. Takano.  Glioblastoma angiogenesis: VEGF resistance solutions and new strategies based on molecular mechanisms of tumor vessel formation , 2012, Brain Tumor Pathology.

[30]  Ganesh Rao,et al.  The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. , 2011, Genes & development.

[31]  L. Ricci-Vitiani,et al.  Expression of EGFRvIII in glioblastoma: prognostic significance revisited. , 2011, Neoplasia.

[32]  A G Sorensen,et al.  Pseudoprogression and Pseudoresponse: Imaging Challenges in the Assessment of Posttreatment Glioma , 2011, American Journal of Neuroradiology.

[33]  M. Chamberlain,et al.  Neural Stem/Progenitors and Glioma Stem-Like Cells Have Differential Sensitivity to Chemotherapy , 2011, Neurology.

[34]  C. Beier,et al.  Chemoresistance of glioblastoma cancer stem cells - much more complex than expected , 2011, Molecular Cancer.

[35]  R. McLendon,et al.  Direct In Vivo Evidence for Tumor Propagation by Glioblastoma Cancer Stem Cells , 2011, PloS one.

[36]  Pieter Wesseling,et al.  A Hypermethylated Phenotype Is a Better Predictor of Survival than MGMT Methylation in Anaplastic Oligodendroglial Brain Tumors: A Report from EORTC Study 26951 , 2011, Clinical Cancer Research.

[37]  Y. Kondo,et al.  The Global DNA Methylation Surrogate LINE-1 Methylation Is Correlated with MGMT Promoter Methylation and Is a Better Prognostic Factor for Glioma , 2011, PloS one.

[38]  G. Reifenberger,et al.  Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas , 2011, International journal of cancer.

[39]  C. Brennan,et al.  Molecular subclassification of diffuse gliomas: Seeing order in the chaos , 2011, Glia.

[40]  K. Hoang-Xuan,et al.  Temozolomide for low-grade gliomas: Predictive impact of 1p/19q loss on response and outcome , 2011, Neurology.

[41]  C. James,et al.  Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074. , 2011, International journal of radiation oncology, biology, physics.

[42]  J. Rich,et al.  Deadly teamwork: neural cancer stem cells and the tumor microenvironment. , 2011, Cell stem cell.

[43]  P. Brastianos,et al.  Prognostic and predictive value of epigenetic silencing of MGMT in patients with high grade gliomas: a systematic review and meta-analysis , 2011, Journal of Neuro-Oncology.

[44]  M. Delorenzi,et al.  Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial , 2011, Molecular Cancer Therapeutics.

[45]  M. Zöller.  CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? , 2011, Nature Reviews Cancer.

[46]  P. Kleihues,et al.  Genetic profile of astrocytic and oligodendroglial gliomas , 2011, Brain Tumor Pathology.

[47]  S. Pastorino,et al.  Transdifferentiation of glioblastoma cells into vascular endothelial cells , 2011, Proceedings of the National Academy of Sciences.

[48]  Paul S Mischel,et al.  Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  L. Ricci-Vitiani,et al.  Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells , 2011, Nature.

[50]  B. Klink,et al.  Glioblastomas with Oligodendroglial Component – Common Origin of the Different Histological Parts and Genetic Subclassification , 2010, Cellular Oncology.

[51]  E. Sen,et al.  Ras regulates interleukin-1β-induced HIF-1α transcriptional activity in glioblastoma , 2011, Journal of Molecular Medicine.

[52]  Rong Wang,et al.  Glioblastoma stem-like cells give rise to tumour endothelium , 2010, Nature.

[53]  Y. Mao,et al.  Chromosome 1p/19q status combined with expression of p53 protein improves the diagnostic and prognostic evaluation of oligodendrogliomas. , 2010, Chinese medical journal.

[54]  C. Sarkar,et al.  O6-Methylguanine DNA Methyltransferase Gene Promoter Methylation Status in Gliomas and Its Correlation With Other Molecular Alterations: First Indian Report With Review of Challenges for Use in Customized Treatment , 2010, Neurosurgery.

[55]  G. Reifenberger,et al.  Patients with IDH 1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH 1-mutated glioblastomas , and IDH 1 mutation status accounts for the unfavorable prognostic effect of higher age : implications for classification of gliomas , 2010 .

[56]  Joel H. Saltz,et al.  The Proneural Molecular Signature Is Enriched in Oligodendrogliomas and Predicts Improved Survival among Diffuse Gliomas , 2010, PloS one.

[57]  J. Wisoff,et al.  Bevacizumab in recurrent high-grade pediatric gliomas. , 2010, Neuro-oncology.

[58]  H. Poulsen,et al.  Cetuximab Insufficiently Inhibits Glioma Cell Growth Due to Persistent EGFR Downstream Signaling , 2010, Cancer investigation.

[59]  Yoshitaka Narita,et al.  Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. , 2010, Genes & development.

[60]  Stephen Yip,et al.  Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers , 2010, The Lancet Neurology.

[61]  C. Sarkar,et al.  MGMT gene promoter methylation in pediatric glioblastomas , 2010, Child's Nervous System.

[62]  Richard G Grundy,et al.  Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  K. Hoang-Xuan,et al.  All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2 , 2010, Neurology.

[64]  Tracy T Batchelor,et al.  Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors. , 2010, Neuro-oncology.

[65]  R. Wilson,et al.  Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. , 2010, Cancer cell.

[66]  A. Brandes,et al.  O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications. , 2010, Neuro-oncology.

[67]  Pieter Wesseling,et al.  IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group , 2010, Clinical Cancer Research.

[68]  M. Wolter,et al.  Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing , 2010, Acta Neuropathologica.

[69]  Howard Colman,et al.  MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. , 2010, Neuro-oncology.

[70]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[71]  G. Fuller,et al.  Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice , 2010, Neuro-oncology.

[72]  C. López-Ginés,et al.  Primary glioblastomas with and without EGFR amplification: Relationship to genetic alterations and clinicopathological features , 2009, Neuropathology : official journal of the Japanese Society of Neuropathology.

[73]  H. Armah.  Malignant Astrocytomas Originate from Neural Stem/Progenitor Cells in a Somatic Tumor Suppressor Mouse Model , 2010 .

[74]  J. Uhm,et al.  The transcriptional network for mesenchymal transformation of brain tumours , 2010 .

[75]  D. Brat,et al.  IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children’s Oncology Group , 2010, Child's Nervous System.

[76]  G. Reifenberger,et al.  MGMT promoter methylation in malignant gliomas: ready for personalized medicine? , 2010, Nature Reviews Neurology.

[77]  Susan M. Chang,et al.  A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. , 2010, Neuro-oncology.

[78]  G. Reifenberger,et al.  NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  M. Nikiforova,et al.  Diagnostic Use of IDH1/2 Mutation Analysis in Routine Clinical Testing of Formalin-Fixed, Paraffin-Embedded Glioma Tissues , 2009, Journal of neuropathology and experimental neurology.

[80]  G. Reifenberger,et al.  Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  T. Tominaga,et al.  Analysis of IDH1 and IDH2 mutations in Japanese glioma patients , 2009, Cancer science.

[82]  T. Mikkelsen,et al.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  P. Kleihues,et al.  IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas , 2009, Clinical Cancer Research.

[84]  Justin C. Grindley,et al.  Tumour-initiating cells: challenges and opportunities for anticancer drug discovery , 2009, Nature Reviews Drug Discovery.

[85]  K. Hoang-Xuan,et al.  Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  David T. W. Jones,et al.  IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. , 2009, Neuro-oncology.

[87]  F. Cognetti,et al.  Pseudoprogression and MGMT status in glioblastoma patients: implications in clinical practice. , 2009, Anticancer research.

[88]  Christian Mawrin,et al.  Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas , 2009, Acta Neuropathologica.

[89]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[90]  J. Rey,et al.  Allelic status of 1p and 19q in oligodendrogliomas and glioblastomas: multiplex ligation-dependent probe amplification versus loss of heterozygosity. , 2009, Cancer genetics and cytogenetics.

[91]  P. Kleihues,et al.  IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. , 2009, The American journal of pathology.

[92]  M. J. van den Bent,et al.  Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  F. Ducray,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[94]  M. Mrugala,et al.  Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. , 2009, Neurology.

[95]  L. Ricci-Vitiani,et al.  Cancer Stem Cell Analysis and Clinical Outcome in Patients with Glioblastoma Multiforme , 2008, Clinical Cancer Research.

[96]  Caterina Giannini,et al.  Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[97]  Andrey Korshunov,et al.  Analysis of the IDH1 codon 132 mutation in brain tumors , 2008, Acta Neuropathologica.

[98]  R. Jenkins,et al.  Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma. , 2008, Cancer journal.

[99]  H. Heinzl,et al.  Anti‐O6‐Methylguanine‐Methyltransferase (MGMT) Immunohistochemistry in Glioblastoma Multiforme: Observer Variability and Lack of Association with Patient Survival Impede Its Use as Clinical Biomarker * , 2008, Brain pathology.

[100]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[101]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[102]  P. Allavena,et al.  Cancer-related inflammation , 2008, Nature.

[103]  A. Brandes,et al.  MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[104]  T. Iwama,et al.  Epidermal Growth Factor Plays a Crucial Role in Mitogenic Regulation of Human Brain Tumor Stem Cells* , 2008, Journal of Biological Chemistry.

[105]  B. O'neill,et al.  MGMT Immunohistochemical Expression and Promoter Methylation in Human Glioblastoma , 2007, Applied immunohistochemistry & molecular morphology : AIMM.

[106]  M. Christmann,et al.  MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. , 2007, DNA repair.

[107]  Qiang Wang,et al.  ErbB receptors: from oncogenes to targeted cancer therapies. , 2007, The Journal of clinical investigation.

[108]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[109]  P. Kleihues,et al.  Genetic pathways to primary and secondary glioblastoma. , 2007, The American journal of pathology.

[110]  Maria Grazia Bruzzone,et al.  Methylation of O6-Methylguanine DNA Methyltransferase and Loss of Heterozygosity on 19q and/or 17p Are Overlapping Features of Secondary Glioblastomas with Prolonged Survival , 2007, Clinical Cancer Research.

[111]  A. Donson,et al.  MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma , 2007, Pediatric blood & cancer.

[112]  Tao Lu,et al.  Dose-dependent cross-talk between the transforming growth factor-β and interleukin-1 signaling pathways , 2007, Proceedings of the National Academy of Sciences.

[113]  T. Khalil,et al.  Interleukin-6 gene amplification and shortened survival in glioblastoma patients , 2007, British Journal of Cancer.

[114]  Mark W. Dewhirst,et al.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.

[115]  K. Black,et al.  Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma , 2006, Molecular Cancer.

[116]  Daniel J Brat,et al.  'Pseudopalisading' Necrosis in Glioblastoma: A Familiar Morphologic Feature That Links Vascular Pathology, Hypoxia, and Angiogenesis , 2006, Journal of neuropathology and experimental neurology.

[117]  U. Bogdahn,et al.  Effective silencing of EGFR with RNAi demonstrates non-EGFR dependent proliferation of glioma cells. , 2006, International journal of oncology.

[118]  K. Hoang-Xuan,et al.  Prognostic impact of molecular markers in a series of 220 primary glioblastomas , 2006, Cancer.

[119]  Thomas D. Wu,et al.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.

[120]  J. Rak,et al.  Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy. , 2006, Seminars in thrombosis and hemostasis.

[121]  A. Korshunov,et al.  The prognostic relevance of molecular alterations in glioblastomas for patients age < 50 years , 2005, Cancer.

[122]  P. Kleihues,et al.  Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. , 2005, Journal of neuropathology and experimental neurology.

[123]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[124]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[125]  Erwin G. Van Meir,et al.  PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. , 2005, Cancer research.

[126]  R. Henkelman,et al.  Identification of human brain tumour initiating cells , 2004, Nature.

[127]  Ugo Orfanelli,et al.  Isolation and Characterization of Tumorigenic, Stem-like Neural Precursors from Human Glioblastoma , 2004, Cancer Research.

[128]  Luca Regli,et al.  Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide , 2004, Clinical Cancer Research.

[129]  Daniel J Brat,et al.  Pseudopalisades in Glioblastoma Are Hypoxic, Express Extracellular Matrix Proteases, and Are Formed by an Actively Migrating Cell Population , 2004, Cancer Research.

[130]  D. Louis,et al.  Age-Dependent Prognostic Effects of Genetic Alterations in Glioblastoma , 2004, Clinical Cancer Research.

[131]  M. Emi,et al.  Silencing effect of CpG island hypermethylation and histone modifications on O6-methylguanine-DNA methyltransferase (MGMT) gene expression in human cancer , 2003, Oncogene.

[132]  Kenji Tada,et al.  Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. , 2003, Cancer research.

[133]  Cynthia Hawkins,et al.  Identification of a cancer stem cell in human brain tumors. , 2003, Cancer research.

[134]  D. Steindler,et al.  Human cortical glial tumors contain neural stem‐like cells expressing astroglial and neuronal markers in vitro , 2002, Glia.

[135]  Y. Yonekawa,et al.  Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C --> A:T mutations of the TP53 tumor suppressor gene. , 2001, Carcinogenesis.

[136]  C. James,et al.  PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. , 2001, Journal of the National Cancer Institute.

[137]  C. Rolhion,et al.  IL-6 gene amplification and expression in human glioblastomas , 2001, British Journal of Cancer.

[138]  Susan M. Chang,et al.  Glioblastoma Patients Epidermal Growth Factor Receptor , and Survival in Analysis of Complex Relationships between Age , p 53 , Updated , 2001 .

[139]  S Bruce,et al.  Temozolomide (Temodar). , 2001, Clinical journal of oncology nursing.

[140]  C. James,et al.  Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. , 2000, Cancer research.

[141]  A Guha,et al.  Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. , 1999, Neurosurgery.

[142]  K. Ichimura,et al.  Chromosome 7 rearrangements in glioblastomas; loci adjacent to EGFR are independently amplified. , 1998, Journal of neuropathology and experimental neurology.

[143]  G. Semenza,et al.  Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1 , 1996, Molecular and cellular biology.

[144]  W. Cavenee,et al.  EGFR gene amplification ‐ rearrangement in human glioblastomas , 1995, International journal of cancer.

[145]  W. Cavenee,et al.  A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[146]  C. James,et al.  Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. , 1991, Cancer research.

[147]  C. James,et al.  Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. , 1990, Proceedings of the National Academy of Sciences of the United States of America.